Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIR178 + PDR001 in Advanced Solid Tumors and DLBCL
NCT03207867Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2017
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label trial of taminadenant in solid tumor, diffuse large B-cell lymphoma (DLBCL), non-small cell lung cancer (NSCLC) and 8 more (4 arms), sponsored by Novartis. Primary endpoint: Overall Response Rate up to 0.5 years. Started Aug 2017; status: terminated.
02
Drugs
taminadenant
03
Conditions
solid tumordiffuse large B-cell lymphoma (DLBCL)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03207867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207867.